a Malignant melanomas usually have an unfavourable prognosis and poor response to chemotherapy. Deregulation of cell proliferation, programmed cell death and intercellular interactions are among several important mechanisms that might lead to malignant transformation of melanocytes and melanoma progression. The S100A1, S100B, Bcl-2 and CD44 antigens have all been described as being involved in different processes of melanoma progression. The expression of these antigens, as well as the rate of cell proliferation, was analyzed retrospectively in melanocytic tumours from 126 patients (32 males and 94 females, age ranging from 11 to 91 years). The series included benign (45 intradermal, 27 compound and eight displastic naevi) and malignant (39 primary and 14 metastatic) melanocytic tumours. The proliferating rate assessed by Ki-67 staining was lower in naevi than in melanomas, with a correlation coefficient of r = 0814. There was no overlap for rate of proliferation between benign and malignant tumours. The expression of S100A1 was low in benign melanocytic tumours and increased in malignant melanomas (r = 0.61). In contrast, a higher percentage of S100B antigen-positive cells were observed in benign melanocytic lesions than in melanomas (Pearson correlation coefficient, 0.627). In addition, positive immunostaining for S100B antigen in malignant melanomas corresponded with the areas with increased proliferating rate. The expression of Bcl-2 was lower in melanomas than in benign melanocytic tumours (r = -0.53). Bcl-2-negative areas within melanomas had an increased proliferating rate. The expression of CD44 showed a large variation both in benign and malignant melanocytic tumours. CD44 antigen expression was higher in melanomas with known metastases than in those without metastases, but this difference was not statistically significant.
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Introduction
The mechanisms that lead to malignant transformation of melanocytic lesions and progression of melanoma are poorly understood. Environmental and genetic factors, as well as deregulation of cell proliferation, programmed cell death and cell-to-cell interactions, seem to be important [1] . Analysis of proteins that are involved in these processes may help to predict the biological behaviour of melanocytic tumours.
The first member of the S100 protein family was originally isolated by Moore [2] as a protein fraction from bovine brain tissue. This protein fraction was named S100 owing to its solubility in 100% saturated ammonium sulphate solution at neutral pH. S100 was purified from bovine brain and defined as brain specific. It is a dimeric protein composed of a and b subunits [3] , which regulates assembly of the cytoskeletal systems such as microtubules and filaments [4] . In addition, it has been suggested that the S100 antigen is involved in cell-cycle regulation and cell division [5] , as well as cell-to-cell communications [6] . The S100 protein family comprises 21 members: S100B, S100A1-A14, S100P, S100Z, calbindin, profilaggrin, trychogyalin and repetin [7] . A different pattern of expression has been shown for S100 protein members in malignant melanoma. In one study, the investigators showed that the S100A1 and S100A3 proteins are not expressed in melanocytic lesions and that S100A2 is found only in selected tumours [8] . In other studies, a low expression of S100A1, S100A2, S100A4 and high expression of S1000A6 has been shown in melanomas [9, 10] . By contrast, one study showed high levels of S100A1 in conjunctival malignant melanocytic lesions [11] . Analysis of S100B in serum showed that it is an independent prognostic marker and may be useful in identifying high-risk cases and monitoring the response to therapy in patients with malignant melanoma [12] [13] [14] [15] .
In addition, S100B interacts with the p53 protein in a calcium-dependent manner and downregulates its function as a tumour suppressor [16] . Thus, inhibitors of the S100B, which restore p53 interaction, may have a potential as a therapeutical agent in metastasizing melanoma [17] . To clarify the somewhat discrepant results of previous studies of S100 protein expression in melanocytic tumours, discussed above, this study focused on S100A1 and S100B expression in benign and malignant melanocytic lesions and in melanoma metastases.
CD44 is a family of transmembrane glycoproteins that serves as the principal ligand for hyaluronate [18] and has been shown to be involved in growth signal transmission, cell binding to endothelium, cell migration and enhancement of cell motility [19] . The role of CD44 protein in cell-to-cell and cell-matrix interactions has led to the suggestion that CD44 might be involved in progression and metastasizing potential of melanomas. At present, the role of CD44 is not clear and some investigators found a loss or reduced expression of CD44 in melanomas [20] [21] [22] , whereas others showed that a high level of CD44 expression is associated with increased metastatic risk and reduced survival [23, 24] . In this study we have evaluated the expression of the CD44 protein in benign and malignant melanocytic lesions including metastatic ones.
The protooncogene Bcl-2 is situated on chromosome 18 and encodes an inner mitochondrial protein [25] . It has been shown that Bcl-2, together with other Bcl-family proteins, is involved in regulation of programmed cell death -apoptosis [26] . It is still unclear how the expression of Bcl-2 protein changes with tumour progression. Whereas elevated levels of Bcl-2 protein in malignant melanomas were demonstrated in one study [27] , a reduced expression of this protein in melanomas was found in other studies [28, 29] . In one study, the cases of malignant melanoma with high Bcl-2 expression were associated with significantly shorter survival [30] , which suggests an important role for Bcl-2 in melanoma progression. In addition, recent preclinical studies in selective target therapy could show that inhibition of Bcl-2 mRNA with oblimersen (Genasense, Genta Inc., 200 Connell Drive, Berkeley Heights, New Jersey, USA) elicits a tumour response from xenograft models of malignant melanoma [31] . Thus, it can be speculated that melanomas with high expression of Bcl-2 might benefit from treatment with Bcl-2 mRNA blocking agents. In this study we have evaluated expression of Bcl-2 in benign and malignant melanocytic lesions.
The Ki-67 protein is located in the nucleus and is detectable in all phases of the cell division cycle except the G 0 phase [32, 33] . Antibodies against the Ki-67 protein are commonly used to determine the growth fraction in different tumours [34] , including those of melanocytic origin [35] . Several reports describe how the rate of cell proliferation in melanomas as measured by Ki-67 staining has a prognostic value [36] [37] [38] and also helps to distinguish benign and malignant melanocytic tumours [39, 40] . In this study, the rate of cell proliferation was evaluated in benign and malignant melanocytic tumours.
The aim of this study was to evaluate whether changes of expression of the S100 group of proteins, adhesion molecule CD44 and apoptosis-related protein Bcl-2, as well as rate of cell proliferation assessed by Ki-67, occur during melanoma progression. Our hypothesis is that specific changes in the protein profile may be characteristic to different phases of melanoma progression, which may be of diagnostic and/or prognostic value.
Materials and methods

Patients
One hundred and twenty-six patients (32 males and 94 females, age ranging from 11 to 91 years, mean 43 years) with benign and malignant melanocytic tumours were included in this retrospective study (Table 1 ). All cases of melanocytic lesions, which were submitted to the Latvian Centre of Pathology during a 1-year period (2001) and had an adequate archival material to satisfy needed analyses, were included in the study.
Tumours classification
Three pathologists independently reviewed the archived primary slides from respective cases. A consensus was then reached among the pathologists in all cases regarding the type of melanocytic tumour using criteria as proposed by the World Health Organization classification of skin tumours [41] . All cases were stratified to the following morphological groups: intradermal naevi, compound naevi, displastic naevi, malignant melanoma and metastatic melanoma.
Immunohistochemistry analysis
Four-micrometer thick sections of formalin-fixed, paraffin-embedded archival material were used for the immunostaining procedure. The technique for microwave antigen retrieval has been used as described earlier [42] . Commercially available monoclonal antibodies to S100A1 (clone DAK-100A1/1), S100B (clone DAK-S100B/2), CD44 (clone DF 1485), Bcl-2 (clone 124) and Ki-67 (clone MIB-1) proteins were used. A high-sensitivity labelled streptavidin-avidin-biotin (LSAB + kit, DAKO, Dako Sweden AB, Stockholm, Sweden) technique [43] was used for the immunoassay following the protocol supplied by the manufacturer. The 3-amino-9-ethylcarbazol chromogene substance was used to produce a redcoloured end-product at the site of the target antigen. Negative and positive controls were used in every staining series. Omitting application of primary antibody was used as negative control. Slides containing brain tissue, squamous carcinoma and breast carcinoma were used as positive controls for S100A1 and S100B, Bcl-2 and CD44 markers, respectively. The positive controls were known to express analyzed proteins. The slides were counterstained with hematoxylin and mounted using water-based mounting media.
Statistical analysis
The number of positive cells was registered using an electronic cell counter (CelloDiff III, Analysis Instrument AB, Sweden) counting 300 cells from three representative fields. All cells with weak-to-strong staining were scored as positive. Statistical analysis was performed using Statistica software (Statsoft, Statsoft Scandinavia AB, Uppsala, Sweden).
Results
The staining intensity for CD44 antigen was much more intensive on the cell surface ( Fig. 1 ) than was that for S100A1, S100B (Fig. 2 ) and Bcl-2 ( Fig. 3) antigens, which were evenly distributed within the cytoplasm. The Ki-67 staining was strictly nuclear (Fig. 4) .
The mean/median, minimum and maximum of positive cells, as well as standard deviation numbers, for each antigen in all morphological groups are shown in Table 2 (Ki-67, S100A1 and S100B) and Table 3 (Bcl-2 and CD44). It can be seen from the tables that the fraction of proliferating cells assessed by Ki-67 staining was considerably lower in groups of benign melanocytic tumours than in primary and metastatic melanoma. This correlation was statistically significant (r = 0.814, r 2 = 0.663). In addition, there was no overlap between benign and malignant tumours. The rate of cell proliferation tended to be higher in primary melanomas that were more than 3 mm thick than in those less than 3 mm thick (Fig. 5) . However, this tendency was not Expression of CD44 in intradermal nevus (Â10, Â20; Dako LSAB + kit staining, haematoxylin counterstain). Expression of S100B in intradermal naevus (Â10, Â20; Dako LSAB + kit staining, haematoxylin counterstain). Expression of Bcl-2 in intradermal naevus (Â10, Â20; Dako LSAB + kit staining, haematoxylin counterstain).
statistically significant. There was no significant difference in proliferation rate between melanomas of different Clark's invasion level (Fig. 6 ).
The fraction of S100A1-positive cells was lower in benign melanocytic tumours than in malignant and metastatic melanomas (Fig. 7) . This difference was statistically significant (r = 0.61, r 2 = 0.376). In contrast, the fraction of S100B-positive cells was higher in the group of benign melanocytic lesions than in malignant and metastatic melanomas (Fig. 7) . The Pearson coefficient and the r 2 values were -0.627 and 0.393, respectively. In malignant melanocytic tumours, the positive staining for S100B corresponded to the areas with an increased proliferation rate (Fig. 8) . Staining for S100A1 was more evenly distributed. The expression of Bcl-2 was higher in benign melanocytic lesions than malignant or metastatic melanomas ( Table 4 Expression of Ki-67 in malignant melanoma ( Â10, Â20; Dako LSAB + kit staining, haematoxylin counterstain). Table 2 The mean, standard deviation, standard error and confidential intervals as well as F and P values of Ki-67, S100A1 and S100B antigen expression in different groups of the melanocytic tumours Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. (Fig. 9) . The variation in the range of Bcl-2 protein expression was less prominent in malignant and metastatic melanomas. Staining for the Bcl-2 antigen in malignant melanomas was more intensive in areas with low proliferation rate.
Expression of CD44 varied markedly in benign and malignant tumours (Fig. 9) . No significant correlation was found between fraction of CD44 positive cells and morphological properties of primary melanomas. In metastatic melanomas, the mean number of CD44-positive cell fractions was higher than in melanomas without metastases: 63.6 and 52.5, respectively. However, this trend did not reach statistical significance.
Discussion
The mechanisms that are responsible for malignant transformation of melanocytic lesions and their biological behaviour are yet to be elucidated. A patient with melanoma less than 1 mm thick may die from extensive metastatic disease, whereas another patient with a thicker melanoma might survive [37, 38] . Thus, the histopathological criteria alone are often not enough to predict the possible clinical course of malignant melanoma. It is obvious that there is a need to identify new markers, which could allow a better prediction of the aggressiveness of melanomas.
In this study we analyzed the proliferation rate by Ki-67 staining, as well as the expression of S100A1, S100B, CD44 and Bcl-2 proteins in benign and malignant melanocytic tumours. The proliferation rate showed a good correlation with morphological properties of different melanocytic tumours. The mean numbers in groups of intradermal, compound and dysplastic naevi were 0.5, 0.9 and 1.2%, respectively. In primary and metastatic melanomas, these numbers were 30 and 32, respectively. Moreover, no overlap was observed between benign and malignant tumours. The gap between the maximum proliferation rate in benign melanocytic tumours and Expression of S100A1 and S100B proteins in different melanocytic tumours.
the minimum in melanomas was 8%. This observation suggests that assessment of the proliferation fraction by Ki-67 staining may be of help in discriminating dysplastic naevi from melanomas. However, it should be pointed out that the basal layers of epidermal cells have a high proliferation rate, which might be of problem when interpretating the results of Ki-67 staining.
The S100 antigen, which was originally thought to be a nervous-system-specific protein, was subsequently found in almost every human tissue [6] , where it has intracellular and extracellular functions. Involvement of the S100 antigen in cell-cycle regulation and cell division [6] , and in cell-to-cell communications [7] , as well as its mitogenic activity, has led to the suggestion that it may be related to the process of tumour progression. Indeed, increased serum levels of the S100 protein have been shown in patients with various tumours, such as melanomas, acute leukaemia, thyroid and renal carcinoma. However, the relation between increased serum levels of S100 proteins and prognosis of the disease was most obvious for melanomas [8] [9] [10] [11] . The measurement of serum levels of the S100B protein is used to identify high-risk cases and to monitor response to therapy in patients with malignant melanoma. In this study, we analyzed the expression of S100A1 and S100B proteins in cells from benign and malignant melanocytic lesions. Intradermal and compound naevi revealed similar expression patterns of these proteins; the fraction of S100A1-positive cells was lower than that of S100B. In dysplastic naevi, the S100A1-positive cell fraction increased, whereas that of S100B remained approximately constant. There is an ongoing discussion between morphologists about whether the dysplastic naevi represent a separate tumour group or are simply 'dysarchitectural' cases of intradermal or compound naevi [44] . Our results clearly show that S100B expression in dysplastic naevi is similar to that seen in intradermal and compound naevi, whereas the expression of S100A1 tends to be higher. A similar pattern was observed in melanomas. It therefore seems that a group of dysplastic naevi may be a separate lesion from intradermal and compound naevi. In primary and metastatic melanomas, we observed a decreased expression of S100B and increased expression of the S100A1 antigen. Although generally decreased, the S100B expression was higher in areas with increased proliferation.
One main feature of CD44 protein expression in melanomas is its upregulation during tumour progression, suggesting that CD44 may be used as a prognostic marker. At present, at least 20 splice variants of CD44 have been identified [19] . In this study, we analyzed the expression of the CD44 protein in naevi and melanomas by a monoclonal antibody, which reacts with all splice variants. We observed that both naevi and melanomas showed a marked variation in the expression of a CD44 protein. In metastatic melanomas, the mean numbers of the CD44-positive cell fraction were higher than in melanomas without metastases, but no significant correlation was found between the expression of the CD44 protein and various and histopathological properties of the melanocytic tumours. Our results can be interpreted to mean that separate variants of the CD44 antigen, rather than its common form, might be involved in the progression of melanocytic tumours. Further studies are needed to identify the specific splice variant of the CD44 that is involved in melanoma progression.
Bcl-2 is involved in the process of programmed cell death (apoptosis) and seems to inhibit multiple cell-deathsignalling pathways, including those mediated by chemotherapeutic agents [27] . These properties of the Bcl-2 protein have led to the suggestion that it may be involved in the progress and drug resistance of melanomas. Results show that naevi express Bcl-2 in higher proportion Expression of S100B in malignant melanoma. Staining intensity of S100B is markedly higher (lower part of the image) in areas, with a higher percentage of Ki-67 staining (upper part of the image). S100, CD44, Bcl-2 and Ki-67 in melanomas Sviatoha et al. 123
than melanomas. In the group of primary and metastatic melanomas, the areas with more intensive Bcl-2 expression corresponded to fields with a lower proliferation rate. This observation suggests that although generally decreased, the Bcl-2 might be active in proliferating tumour cells. The meaning of this observation is unclear and requires an additional study for clarification. In addition, there are cases of melanoma with high levels of Bcl-2, which might be a subject for selective Bcl-2 mRNA blocking therapy.
We hypothesized that steps of melanoma progression may be reflected in the expression of specific proteins and changes in the rate of cell proliferation. Indeed, the study showed that expression of subunits of the S100 protein has a clear pattern, which may have diagnostic implications as well as use in monitoring purposes. As expected, the rate of cell proliferation assessed by Ki-67 increases with melanoma progression. As there is no overlap between malignant and benign melanocytic lesions, this observation may be used in diagnostic workup to discriminate between groups of benign and malignant melanocytic tumours. However, the number of cases in groups of metastatic melanomas and dysplastic naevi is somewhat small compared with the other morphological groups analyzed in the study. As CD44 represents a universal marker for all splice variants, its expression does not reflect changes of subtypes of this protein. expression of the various S100 subtypes in melanocytic tumours. Such studies may add valuable information concerning genesis and progression of melanocytic tumours.
In conclusion, the proliferation rate assessed by Ki-67 staining correlates well with morphological properties of melanocytic tumours and may be used to distinguish dysplastic naevi from malignant melanomas. The expression of the S100A1 and S100B antigens in melanocytic tumours showed an interesting pattern; high levels of S100B and low levels of S100A1 were observed in naevi, whereas in melanomas a decreased level of S100B was observed as compared with that of S100A1. Areas with intense S100B staining corresponded to parts of tumours with an increased proliferation rate. Bcl-2 expression was higher in benign melanocytic lesions as compared with melanomas.
